Terms: = Endocrine gland cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID
295 results:
1. Expression landscape of cancer-foxp3 and its prognostic value in pancreatic adenocarcinoma.
Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
[TBL] [Abstract] [Full Text] [Related]
2. An immunogenic cell death-related gene expression signature in predicting prognosis of pancreatic ductal adenocarcinoma.
Wang X; Ren T; Liao C; Xie Y; Cao J
BMC Genomics; 2024 Feb; 25(1):205. PubMed ID: 38395786
[TBL] [Abstract] [Full Text] [Related]
3. High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer.
Zhang G; Shu Z; Yu J; Li J; Yi P; Wu B; Deng D; Yan S; Li Y; Ren D; Hou Y; Lan C
Front Immunol; 2024; 15():1341209. PubMed ID: 38352864
[TBL] [Abstract] [Full Text] [Related]
4. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
5. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity.
Ishikawa Y; Yamazaki Y; Tezuka Y; Omata K; Ono Y; Tokodai K; Fujishima F; Kawanabe S; Katabami T; Ikeya A; Yamashita M; Oki Y; Nanjo H; Satoh F; Ito A; Unno M; Kamei T; Sasano H; Suzuki T
J Steroid Biochem Mol Biol; 2024 Apr; 238():106462. PubMed ID: 38232786
[TBL] [Abstract] [Full Text] [Related]
6. Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma.
Li S; Chen Z; Liu M; Li L; Cai W; Lian ZX; Guan H; Xu B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214937
[TBL] [Abstract] [Full Text] [Related]
7. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C; Derangère V; Gaudillière-Le Dain G; Huppe T; Rageot D; Ilie A; Vienot A; Borg C; Monnien F; Bibeau F; Truntzer C; Ghiringhelli F;
Oncoimmunology; 2024; 13(1):2294563. PubMed ID: 38169969
[TBL] [Abstract] [Full Text] [Related]
8. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract] [Full Text] [Related]
9. Identification of foxp3
Gong R; Chen X; Sun X; Zhang Y; Wang J; Yu Q; Lei K; Ren H
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C294-C303. PubMed ID: 38047300
[TBL] [Abstract] [Full Text] [Related]
10. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
[TBL] [Abstract] [Full Text] [Related]
12. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
13. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis.
Zhang S; Fang W; Zhou S; Zhu D; Chen R; Gao X; Li Z; Fu Y; Zhang Y; Yang F; Zhao J; Wu H; Wang P; Shen Y; Shen S; Xu G; Wang L; Yan C; Zou X; Chen D; Lv Y
Nat Commun; 2023 Aug; 14(1):5123. PubMed ID: 37612267
[TBL] [Abstract] [Full Text] [Related]
14. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian cancer: Relationship with Histological and Clinical Features.
Spagnolo E; Martinez A; Mascarós-Martínez A; Marí-Alexandre J; Carbonell M; González-Cantó E; Pena-Burgos EM; Mc Cormack BA; Tomás-Pérez S; Gilabert-Estellés J; López-Carrasco A; Hidalgo P; Ángeles MA; Redondo A; Gallego A; Hernández A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569458
[TBL] [Abstract] [Full Text] [Related]
16. IL-17 A correlates with disease progression in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Gupta R; Mukherjee S; Sachdeva N; Sood A; Dey P; Radotra B; Bhansali A
Diagn Pathol; 2023 Aug; 18(1):93. PubMed ID: 37563607
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract] [Full Text] [Related]
18. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
[TBL] [Abstract] [Full Text] [Related]
19. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
De Simoni O; Dal Santo L; Scarpa M; Munari G; Spolverato YC; Scapinello A; Lonardi S; Soldà C; Bergamo F; Fantin A; Bardini R; Pilati P; Fassan M; Gruppo M
Curr Oncol; 2023 Jun; 30(6):5515-5528. PubMed ID: 37366900
[TBL] [Abstract] [Full Text] [Related]
20. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
[TBL] [Abstract] [Full Text] [Related]
[Next]
